Top news from ESC: Impact of naps on CV health, results from DAPA-CKD, LoDoCo2 and more
Click Here to Manage Email Alerts
Healio and Cardiology Today have compiled a list of the most-read news from the virtual European Society of Cardiology Congress.
Readers were most interested in the CV impact of long naps, saliva-based testing for MI, results from the LoDoco2 trial and more.
Naps longer than 1 hour may confer risk for CVD, mortality
Adults who napped longer than 1 hour per day had elevated risk for CVD and mortality compared with those who did not nap at all, according to a meta-analysis. Read more
Saliva-based rapid test for heart attack feasible
Using a novel saliva-based rapid cardiac troponin I test to diagnose MI was feasible, according to the results of a preliminary study. Read more
LoDoCo2: Low-dose colchicine reduces CV events by 31% on top of optimal medical therapy
In patients with chronic coronary disease, adding low-dose colchicine to optimal medical therapy reduced risk for CV events by 31%, according to results of the LoDoCo2 trial. Read more
Dapagliflozin cuts renal, CV events in CKD, regardless of diabetes status
In the DAPA-CKD trial, treatment with the SGLT2 inhibitor dapagliflozin reduced risk for worsening renal function and death due to CVD or renal disease in patients with chronic kidney disease, both with and without type 2 diabetes. Read more
No clinical benefit of ACE inhibitor, ARB suspension in mild to moderate COVID-19
In patients hospitalized with mild or moderate COVID-19, suspending ACE inhibitors and angiotensin receptor blockers for 30 days, compared with continued treatment, did not impact the number of days alive and out of hospital. Read more
COLCOT: Early use of colchicine beneficial after MI
In a substudy of the COLCOT trial, patients with MI benefited the most from colchicine if it was initiated early in their hospital stay. Read more
Stress, anxiety in adolescence increases MI risk later in life
Nonpsychotic mental disorders in adolescent boys increased the risk for MI later in life, researchers reported. Read more
Empagliflozin lowers CV death, hospitalizations in HFrEF with or without diabetes
The SGLT2 inhibitor empagliflozin improved CV and renal outcomes in patients with HF with reduced ejection fraction, regardless of diabetes status, according to results of the EMPEROR-Reduced trial. Read more.
EAST-AFNET 4: Early rhythm control for AF reduces risk for poor CV outcomes
Rhythm control therapy within 1 year of atrial fibrillation diagnosis in patients with CV conditions reduced the risk for CV events compared with usual care. Read more
ESC guideline on AF emphasizes shared decision-making
A new atrial fibrillation guideline from the European Society of Cardiology advocates collaboration between clinicians and patients for AF treatment options. Read more
Collapse
Healio Coverage
Click Here to Manage Email Alerts